MCID: BCL017
MIFTS: 61

B-Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for B-Cell Lymphoma

MalaCards integrated aliases for B-Cell Lymphoma:

Name: B-Cell Lymphoma 12 53 29 15 38
Lymphoma, B-Cell 53 44 40
B-Cell Lymphomas 75 15
B-Cell Lymphocytic Neoplasm 12
Lymphoma B-Cell 55

Classifications:



External Ids:

Disease Ontology 12 DOID:707
MeSH 44 D016393
NCIt 50 C27907 C3457
SNOMED-CT 68 1929004
ICD10 33 C85.1
UMLS 72 C0079731

Summaries for B-Cell Lymphoma

NIH Rare Diseases : 53 B-cell lymphoma refers to types of non-Hodgkin lymphoma that are characterized by abnormalities of the "B-cells" (a type of white blood cell that makes antibodies to help fight infection). The condition may grow and spread slowly with few symptoms (also known as indolent lymphoma) or may be very aggressive with severe symptoms. When present, signs and symptoms may include swollen lymph nodes in the neck, armpit, or groin; abdominal pain; fatigue; fever; night sweats; and/or weight loss. The underlying cause of B-cell lymphoma is poorly understood. However, the condition can be associated with genetic abnormalities, environmental factors, viruses, immunodeficiency states, and connective-tissue disorders. Treatment is based on many factors, including the severity of the condition and the associated signs and symptoms.

MalaCards based summary : B-Cell Lymphoma, also known as lymphoma, b-cell, is related to primary mediastinal b-cell lymphoma and primary mediastinal large b-cell lymphoma. An important gene associated with B-Cell Lymphoma is MIR17 (MicroRNA 17), and among its related pathways/superpathways are NF-KappaB Family Pathway and T cell receptor signaling pathway. The drugs Oxaliplatin and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A non-Hodgkin lymphoma that has material basis in B cells.

Wikipedia : 75 Lymphoma is a group of blood cancers that develop from lymphocytes (a type of white blood cell). The... more...

Related Diseases for B-Cell Lymphoma

Diseases in the B-Cell Lymphoma family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1193)
# Related Disease Score Top Affiliating Genes
1 primary mediastinal b-cell lymphoma 35.7 REL BCL6 BCL11A
2 primary mediastinal large b-cell lymphoma 35.6 MYC IRF4 BCL6
3 nodal marginal zone b-cell lymphoma 35.5 MALT1 BCL6
4 primary cutaneous marginal zone b-cell lymphoma 35.5 MALT1 IRF4 BCL10
5 primary cutaneous diffuse large b-cell lymphoma, leg type 35.5 MYD88 IRF4
6 marginal zone b-cell lymphoma 35.4 MYD88 MME MALT1 IRF4 CCND1 BCL6
7 intravascular large b-cell lymphoma 35.2 MME BCL6
8 t-cell/histiocyte rich large b cell lymphoma 35.2 MME BCL6
9 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 35.1 MYC BCL6
10 lymphoma, mucosa-associated lymphoid type 35.0 MME MALT1 IRF4 CCND1 BCL6 BCL10
11 diffuse large b-cell lymphoma 34.9 REL MYD88 MYC MME MDM2 MALT1
12 follicular lymphoma 34.0 MYC MME IRF4 CCND1 BCL6 BCL10
13 primary effusion lymphoma 34.0 MYC IRF4 BCL6
14 lymphoma, non-hodgkin, familial 32.5 MYC MME MDM2 MALT1 IRF4 CCND1
15 burkitt lymphoma 32.5 TP53COR1 PVT1 MYC MME BCL6
16 central nervous system lymphoma 32.5 MYD88 MALT1 BCL6
17 lymphoma 32.4 REL PVT1 MYC MALT1 GAS5 CCND1
18 leukemia, chronic lymphocytic 32.3 CCND1 BCL6 BCL3 BCL10
19 lymphocytic leukemia 32.2 MYD88 MYC MME HOTAIR BCL3
20 testicular lymphoma 32.1 MYD88 MME BCL6
21 chromosomal triplication 32.0 MALT1 BCL6
22 lymphoma, hodgkin, classic 32.0 PVT1 MME MIR20A BCL6
23 plasmacytoma 31.8 PVT1 MYC IRF4
24 mediastinal malignant lymphoma 31.6 REL BCL6 BCL11A
25 mature b-cell neoplasm 31.3 PVT1 MYC MME BCL6
26 mantle cell lymphoma 31.3 MYC MME MDM2 MALT1 MALAT1 GAS5
27 intestinal disease 31.3 MYC CCND1 BCL6
28 ovarian lymphoma 31.1 MYC MME
29 lymphatic system cancer 31.1 MYC MME BCL6
30 heart lymphoma 31.0 MME BCL6
31 follicular lymphoma 1 30.9 BCL6 BCL10
32 hematologic cancer 30.7 PVT1 MYC MME BCL6
33 monoclonal paraproteinemia 30.6 MYD88 CCND1
34 retinoblastoma 30.5 MDM2 MALAT1 HOTAIR CCND1
35 leukemia, acute myeloid 30.1 TUG1 MYC MME MALAT1 HOTAIR
36 cholangiocarcinoma 29.9 TUG1 MME MALAT1 CCND1
37 endometrial cancer 29.3 TUG1 MYC MME MDM2 HOTAIR GAS5
38 nasopharyngeal carcinoma 29.3 PVT1 MYC MDM2 MALAT1 HOTAIR GAS5
39 thyroid cancer, nonmedullary, 1 29.2 PVT1 MALAT1 HOTAIR GAS5
40 small cell cancer of the lung 29.2 TUG1 MYC MALAT1 HOTAIR
41 myeloma, multiple 29.2 TUG1 PVT1 MYC MME MALAT1 IRF4
42 medulloblastoma 29.1 MYC MIR20A MIR17 HOTAIR CCND1
43 glioblastoma 29.0 TUG1 MYC MDM2 MALAT1 HOTAIR GAS5
44 lung cancer susceptibility 3 28.9 TUG1 MALAT1 HOTAIR GAS5 CCND1
45 esophageal cancer 28.9 PVT1 MYC MDM2 MALAT1 HOTAIR GAS5
46 renal cell carcinoma, nonpapillary 28.9 TUG1 PVT1 MME MALAT1 HOTAIR GAS5
47 osteogenic sarcoma 28.7 TUG1 PVT1 MALAT1 HOTAIR GAS5
48 bladder cancer 28.5 TUG1 PVT1 MYC MDM2 MALAT1 HOTAIR
49 ovarian cancer 28.1 TUG1 PVT1 MYC MDM2 MALAT1 HOTAIR
50 malignant glioma 28.1 TUG1 TP53COR1 PVT1 HOTAIR GAS5

Graphical network of the top 20 diseases related to B-Cell Lymphoma:



Diseases related to B-Cell Lymphoma

Symptoms & Phenotypes for B-Cell Lymphoma

MGI Mouse Phenotypes related to B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 BCL10 BCL11A BCL3 BCL6 CCND1 IRF4
2 immune system MP:0005387 9.4 BCL10 BCL11A BCL3 BCL6 CCND1 IRF4

Drugs & Therapeutics for B-Cell Lymphoma

Drugs for B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 507)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4 61825-94-3 5310940 9887054 43805 6857599
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
4
Ifosfamide Approved Phase 4 3778-73-2 3690
5
Mechlorethamine Approved, Investigational Phase 4 51-75-2 4033
6
Epirubicin Approved Phase 4 56420-45-2 41867
7
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
8
Lithium carbonate Approved Phase 4 554-13-2
9 Liver Extracts Phase 4
10
Apatinib Phase 4 811803-05-1
11
Isophosphamide mustard Phase 4 0
12 Central Nervous System Depressants Phase 4
13 Tranquilizing Agents Phase 4
14 Antidepressive Agents Phase 4
15 Psychotropic Drugs Phase 4
16 Antimanic Agents Phase 4
17
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
18
Pixantrone Approved, Investigational Phase 3 144510-96-3
19
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
20
Mercaptopurine Approved Phase 3 50-44-2 667490
21
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
22 Orange Approved Phase 3
23
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
24
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
25
Promethazine Approved, Investigational Phase 3 60-87-7 4927
26
Acetaminophen Approved Phase 3 103-90-2 1983
27
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
28
Morphine Approved, Investigational Phase 3 57-27-2 5288826
29
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
30
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
31
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
32
Chlorambucil Approved Phase 3 305-03-3 2708
33
Ribavirin Approved Phase 3 36791-04-5 37542
34
Palivizumab Approved, Investigational Phase 3 188039-54-5
35
Dalteparin Approved Phase 3 9005-49-6
36
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
37
Ofloxacin Approved Phase 3 82419-36-1 4583
38
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
39
Captopril Approved Phase 3 62571-86-2 44093
40
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
41
Acyclovir Approved Phase 3 59277-89-3 2022
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
44
Tazobactam Approved Phase 3 89786-04-9 123630
45
Piperacillin Approved Phase 3 66258-76-2 43672
46
Vancomycin Approved Phase 3 1404-90-6 441141 14969
47
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
48
Rasburicase Approved, Investigational Phase 2, Phase 3 134774-45-1
49
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2
50
Vinblastine Approved Phase 3 865-21-4 241903 13342

Interventional clinical trials:

(show top 50) (show all 1930)
# Name Status NCT ID Phase Drugs
1 A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma Unknown status NCT01949818 Phase 4 Yangzhengxiaoji capsule combined with CHOP regimen;CHOP regimen
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study Completed NCT03376958 Phase 4 Apatinib
4 LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV) Completed NCT00466258 Phase 4 R-CHOP;Highly active antiretroviral therapy;Central nervous system (CNS) prophylaxis;Prophylaxis of opportunistic infections and support treatment
5 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
6 A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
7 Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma. Recruiting NCT02752815 Phase 4 Rituximab;Cyclophosphamide;Epirubicin;Vincristine;Prednisone
8 Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma Recruiting NCT03513601 Phase 4 (R)-CHOP regimen;(R)-CVP regimen
9 A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma Recruiting NCT03579082 Phase 4 Decitabine
10 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
11 Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs) Recruiting NCT03071822 Phase 4 cisplatin;ifosfamide;gemcitabine;L-asparaginase;etoposide;dexamethasone
12 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
13 Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia Recruiting NCT03185208 Phase 4 Lithium Carbonate;Placebo oral capsule
14 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Active, not recruiting NCT01990534 Phase 4 Brentuximab vedotin
15 Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials. Enrolling by invitation NCT03229200 Phase 4 Ibrutinib
16 Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial Not yet recruiting NCT02992834 Phase 4
17 R-CHOP Therapy Compared With R-CHOP Plus Biocell Natural Killer Mixture in Patients With DLBCL (Diffuse Large B Cell Lymphoma);A Randomized, Open-label,Multi-center Trail Unknown status NCT00846157 Phase 3
18 Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions Unknown status NCT02867553 Phase 3 rituximab
19 A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL) Unknown status NCT02867566 Phase 3 IBI301 plus CHOP;Rituximab plus CHOP
20 Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma Unknown status NCT02617485 Phase 3 Rituximab;Doxorubicin;Vincristine;Cyclophosphamide;prednisone
21 A Randomised Multicentric Phase III Study for the Treatment of Young Patients With High Risk (IPI 2-3) Diffuse Large B-Cell Lymphoma. Dose Dense Chemotherapy + Rituximab +/- Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cells. Unknown status NCT00499018 Phase 3 Rituximab;Ciclofosfamide;Doxorubicina;Vincristina;Prednisone;Pegfilgrastim;Mitoxantrone;ARA-C;Lenograstim;BCNU;ARA-C;VP-16;Ciclofosfamide;Doxorubicina;Vincristina
22 Phase 3 Study of 30Gy Versus 40Gy Involved-field Radiotherapy in Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
23 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
24 A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma Unknown status NCT03151044 Phase 3 High-dose Epirubicin Combined with CVP ± Rituximab;Standard-dose Epirubicin Combined with CVP ± Rituximab
25 Incidence of HBV Reactivation in HBsAg Negative/HBcAb Positive Diffuse Large B Cell Lymphoma or High Grade Follicular Lymphoma Patients: A Prospective Study Unknown status NCT01210287 Phase 2, Phase 3 nucleoside analog reverse transcriptase inhibitor
26 A Phase III, Open-Label, Prospective, Two-Armed, Multicenter, Randomized, Group Sequential Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study Regimen Versus Observation in Patients With Diffuse Large B-Cell Lymphoma Who Are in Complete Remission After First-Line CHOP-Rituximab (CHOP-R) Therapy Unknown status NCT00322218 Phase 3 Zevalin Therapeutic Regimen
27 Phase III Study of CHOP-14 Plus or Minus Alemtuzumab in Peripheral T-cell Lymphoma of the Elderly Unknown status NCT00725231 Phase 3 chemotherapy
28 Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial Unknown status NCT01933711 Phase 3 rituximab
29 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
30 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
31 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
32 A Randomized Phase III Trial Comparing the Combination of Fludarabine, BBR 2778 (Pixantrone) and Rituximab (FP-R) With the Combination of Fludarabine and Rituximab (F-R) in the Treatment of Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
33 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
34 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
35 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
36 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
37 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
38 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
39 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
40 Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma Unknown status NCT00003650 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisone;vincristine sulfate
41 Rituximab + Standard CHOP (R・S-CHOP) vs Rituximab+ Bi-weekly CHOP (R・Bi-CHOP) RCT(Phase II/III) for Stage III/IV Low-grade B-cell Lymphoma (LowBNHL-RS/BiCHOP-P2/3) (JCOG0203) Completed NCT00147121 Phase 2, Phase 3 Rituximab + Standard CHOP;Rituximab + Bi-weekly CHOP
42 An Open-labeled, Multi-center, Randomized, Prospective Phase III Study Comparing CMAB304 in Combination With CHOP to CHOP Alone With CMAB304 Maintenance in Patients With DLBCL Completed NCT01459887 Phase 3 CHOP combined with CMAB304;CHOP, CMAB304
43 Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma Completed NCT00168740 Phase 3 rituximab
44 A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL) Completed NCT01148446 Phase 3 Cyclophosphamide;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Prednisone;Epirubicin;Vinblastine;Rituximab;G-CSF
45 Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma Completed NCT00169130 Phase 2, Phase 3 doxorubicin;cyclophosphamide
46 A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy Completed NCT00790036 Phase 3 Everolimus;Everolimus Placebo
47 A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Aggressive B-cell Lymphoma: NHL-13 Completed NCT00400478 Phase 3 Rituximab
48 A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL) Completed NCT01649856 Phase 3 CHOP;rituximab [MabThera/Rituxan];rituximab [MabThera/Rituxan]
49 A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A Completed NCT01724021 Phase 3 Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP);Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP);Bendamustine;Rituximab;Rituximab;Rituximab;Rituximab
50 A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line Completed NCT02268045 Phase 3

Search NIH Clinical Center for B-Cell Lymphoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ibritumomab tiuxetan
Ibrutinib
rituximab

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, b-cell

Genetic Tests for B-Cell Lymphoma

Genetic tests related to B-Cell Lymphoma:

# Genetic test Affiliating Genes
1 B-Cell Lymphoma 29

Anatomical Context for B-Cell Lymphoma

MalaCards organs/tissues related to B-Cell Lymphoma:

41
B Cells, T Cells, Bone, Bone Marrow, Breast, Lung, Liver

Publications for B-Cell Lymphoma

Articles related to B-Cell Lymphoma:

(show top 50) (show all 25508)
# Title Authors PMID Year
1
MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. 38 88
18941111 2009
2
Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. 9 38
20428773 2010
3
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation. 9 38
20442643 2010
4
IRF4 expression without IRF4 rearrangement is a general feature of primary cutaneous diffuse large B-cell lymphoma, leg type. 9 38
20054341 2010
5
Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. 9 38
20190733 2010
6
Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution. 9 38
20331331 2010
7
The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma. 9 38
20459572 2010
8
Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 9 38
20371444 2010
9
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. 9 38
20371683 2010
10
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. 9 38
20122924 2010
11
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. 9 38
19965662 2010
12
Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. 9 38
20303013 2010
13
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. 9 38
19889619 2010
14
Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent. 9 38
19714753 2010
15
Xeroderma pigmentosum skin: an immune privilege site for tumor development. 9 38
19719835 2010
16
CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. 9 38
20093404 2010
17
Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. 9 38
20062012 2010
18
Translocations involving MUM1 are rare in diffuse large B-cell lymphoma. 9 38
18815567 2010
19
Epstein-Barr virus encoded LMP1 downregulates TCL1 oncogene through miR-29b. 9 38
19966860 2010
20
An uncommon case of de novo CD10+ CD5- mantle cell lymphoma mimics follicle center B cell lymphoma. 9 38
20490333 2010
21
Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 9 38
20093241 2010
22
Cyclins D3 and E go hand in hand with Cdk4/6 in diffuse large B-cell lymphoma. 9 38
20130454 2010
23
Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. 9 38
20107311 2010
24
CD81 protein is expressed at high levels in normal germinal center B cells and in subtypes of human lymphomas. 9 38
20004001 2010
25
Deregulation of H3K27 methylation in cancer. 9 38
20104248 2010
26
Mechanisms of chromosomal rearrangement in the human genome. 9 38
20158866 2010
27
Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and non-germinal center B-cell subtypes. 9 38
20174727 2010
28
Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase. 9 38
20103729 2010
29
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. 9 38
20081860 2010
30
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. 9 38
19965678 2010
31
Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. 9 38
19857547 2010
32
Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. 9 38
19797725 2010
33
[Correlation of Bcl-2 with immunological subtype and prognosis in diffuse large B-cell lymphoma.]. 9 38
20302777 2010
34
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. 9 38
20054396 2010
35
Extracellular tumor-related mRNA in plasma of lymphoma patients and survival implications. 9 38
20016842 2009
36
Is inactivation of O6-methylguanine DNA methyltransferase still a favorable prognostic factor of patients with diffuse large B-cell lymphoma in the era of R-CHOP chemotherapy? 9 38
19860620 2009
37
REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. 9 38
19289490 2009
38
Long-range oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. 9 38
20010689 2009
39
[Construction of expression plasmid for fused idiotypic DNA vaccine of B-cell lymphoma]. 9 38
20030925 2009
40
Analysis of CXCL9 and CXCR3 expression in a case of intravascular large B-cell lymphoma. 9 38
19766346 2009
41
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. 9 38
19775297 2009
42
Gene expression profiling of diffuse large B-cell lymphoma -- comparison depending on the CD21 antigen expression. 9 38
20009432 2009
43
Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. 9 38
19897720 2009
44
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. 9 38
19814686 2009
45
Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. 9 38
19786664 2009
46
Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. 9 38
20032398 2009
47
Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. 9 38
19917125 2009
48
Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells. 9 38
19725825 2009
49
[Clinicopathologic and immunohistochemical study of intra-abdominal non-Hodgkin B-cell lymphoma occurring in children]. 9 38
20079016 2009
50
[Immunohistochemical study using T-cell lymphoma antibody 1 and CD44 in diagnosis of Burkitt's lymphoma]. 9 38
20079013 2009

Variations for B-Cell Lymphoma

Cosmic variations for B-Cell Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM12475 CDKN2A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,B cell lymphoma unspecified c.238C>T p.R80* 9:21971121-21971121 0

Expression for B-Cell Lymphoma

Search GEO for disease gene expression data for B-Cell Lymphoma.

Pathways for B-Cell Lymphoma

Pathways related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.5 REL MYD88 MALT1 BCL3 BCL10
2
Show member pathways
12.37 REL MALT1 IRF4 BCL10
3 12.32 MYC MIR20A MIR17 MDM2 CCND1
4 12.25 REL MYD88 MALT1 IRF4 BCL6 BCL10
5
Show member pathways
12.2 REL MYC MDM2 CCND1
6
Show member pathways
12.09 MYC MIR20A MIR17 MDM2 CCND1
7 12.03 REL MYC MDM2 BCL6
8 11.84 MYC MDM2 CCND1
9
Show member pathways
11.83 REL MYC MALT1 IRF4 BCL6 BCL10
10 11.8 MYC MDM2 CCND1
11 11.77 MYC MDM2 CCND1 BCL6
12 11.74 MYD88 MALT1 BCL10
13 11.73 MYC IRF4 CCND1 BCL6
14
Show member pathways
11.69 REL MYD88 IRF4
15 11.66 MYC MDM2 CCND1
16 11.53 MYC MDM2 CCND1
17
Show member pathways
11.46 REL MYC CCND1
18
Show member pathways
11.34 REL MYD88 MDM2 MALT1 BCL3 BCL10
19 11.1 REL MYC MDM2 CCND1
20 10.71 REL BCL3

GO Terms for B-Cell Lymphoma

Cellular components related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.43 MYD88 MYC MDM2 MALT1 BCL3 BCL10
2 CBM complex GO:0032449 8.62 MALT1 BCL10

Biological processes related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.9 MALT1 BCL6 BCL3 BCL10
2 negative regulation of apoptotic process GO:0043066 9.88 MYD88 MYC MDM2 MALT1 BCL6 BCL3
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.76 REL MYD88 MALT1 BCL10
4 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.71 REL BCL3 BCL10
5 positive regulation of cell cycle GO:0045787 9.69 MYC MDM2 CCND1
6 cytokine-mediated signaling pathway GO:0019221 9.65 MYD88 MYC IRF4 CCND1 BCL6
7 response to iron ion GO:0010039 9.62 MDM2 CCND1
8 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.62 MYD88 MIR17
9 negative regulation of toll-like receptor signaling pathway GO:0034122 9.61 MIR17 IRF4
10 cellular response to estrogen stimulus GO:0071391 9.61 MYC MDM2
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.61 MIR20A MIR17 MDM2
12 response to magnesium ion GO:0032026 9.59 MDM2 CCND1
13 response to molecule of bacterial origin GO:0002237 9.58 MALT1 BCL10
14 immunoglobulin mediated immune response GO:0016064 9.58 MYD88 BCL10
15 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.57 MIR20A MIR17
16 germinal center formation GO:0002467 9.55 BCL6 BCL3
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.54 MYD88 MALT1 BCL10
18 response to fungus GO:0009620 9.52 MALT1 BCL10
19 regulation of T cell receptor signaling pathway GO:0050856 9.49 MALT1 BCL10
20 re-entry into mitotic cell cycle GO:0000320 9.48 MYC CCND1
21 cellular response to hypoxia GO:0071456 9.46 MYC MIR17 MDM2 MALAT1
22 negative regulation of gene expression GO:0010629 9.35 REL MYC MIR20A MIR17 MDM2
23 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.32 MIR20A MIR17
24 positive regulation of interleukin-10 biosynthetic process GO:0045082 8.62 IRF4 BCL3
25 positive regulation of transcription, DNA-templated GO:0045893 10.03 REL MYC IRF4 BCL3 BCL10
26 negative regulation of transcription by RNA polymerase II GO:0000122 10.03 REL MYC MDM2 CCND1 BCL6 BCL11A

Molecular functions related to B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity GO:0003700 9.73 REL MYC IRF4 BCL6 BCL3 BCL11A
2 kinase activator activity GO:0019209 9.16 MALT1 BCL10
3 protein self-association GO:0043621 9.13 MYD88 MALT1 BCL10
4 transcription factor binding GO:0008134 9.02 MYC IRF4 CCND1 BCL3 BCL10

Sources for B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO